Antipsychotic Drug Recalled for Failed Quality Control Test
Ascend Laboratories is recalling 135 bottles of Aripiprazole 20 mg tablets nationwide due to failure of spectroscopic identification testing, indicating the product may not meet established quality standards.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II recall of a prescription medication that failed critical identity testing (spectroscopic identification). While no illnesses or injuries have been reported, a drug that cannot be verified to meet identity specifications represents a risk-of-harm product, warranting a High severity rating.
Plain-English summary
Ascend Laboratories, LLC is recalling 135 bottles of Aripiprazole 20 mg tablets distributed nationwide. The recall was initiated because the product failed spectroscopic identification testing by infrared (IR) analysis, meaning the tablets do not meet established quality and identity specifications.
Aripiprazole is a prescription antipsychotic medication. When a drug fails identity testing, it indicates uncertainty about the product's chemical composition and purity, raising concerns about whether the medication is correctly formulated and safe to use.
The affected lot is #22143120 with an expiration date of June 2024. If you have Aripiprazole tablets from this lot, do not use them. Contact your pharmacy or healthcare provider immediately for guidance on obtaining a replacement prescription.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Ascend Laboratories, LLC
- Category
- Drug — Antipsychotic
- Affected units
- 135
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #22143120
- Exp. Date: June 2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole 30mg bottle contained voriconazole 50mg tablets instead
FDA (Drugs) · 2026-06-24
- HighAripiprazole 10 mg tablets recalled after testing superpotent in one lot
FDA (Drugs) · 2025-09-24
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- ModeratePrescription drug aripiprazole tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighAccord Healthcare Recalls Aripiprazole Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Ascend Laboratories, LLC
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Over Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateFDA Recalls Amlodipine and Olmesartan Tablets Over Failed Dissolution Test
FDA (Drugs) · 2026-07-29
- ModerateDabigatran Etexilate Capsules Recalled Over Impurity Test Failure
FDA (Drugs) · 2026-07-29
Same hazard · out of specification
See all →- ModerateAquacel Ag Surgical SP Surgical Dressing Recalled for Out-of-Specification Thickness
FDA (Devices) · 2026-07-15
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighMedline pre-connected urethral catheterization trays fail performance specifications
FDA (Devices) · 2026-06-24
- HighMedline 15 Fr urethral catheterization trays fail performance specifications
FDA (Devices) · 2026-06-24
- HighMedline vasectomy reversal kits contain catheters failing performance specifications
FDA (Devices) · 2026-06-24